SCHEMBL30786198

SCHEMBL30786198

CN1CCN(c2ccc(Br)nc2)CC1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.64
CHRNA4 P43681 3/20 0.64
MAPT P10636 3/20 0.49
HTR3A P46098 2/20 0.49
GAA P10253 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
GLA P06280 1/20 0.49
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 2/20 0.48
ADRA2C P18825 2/20 0.48
GFER P55789 1/20 0.48
PTK2B Q14289 1/20 0.48
ESR2 Q92731 1/20 0.48
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ADRA2A P08913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5199765 1.00 CHRNB2 (0.64) CHRNB2CHRNA4MAPTHTR3AGAA
SCHEMBL25194861 0.85 CHRNB2 (0.51) CHRNB2CHRNA4
SCHEMBL29067311 0.82 CHRNB2 (0.77) CHRNB2CHRNA4MAPTGAAKMT2A
SCHEMBL27067392 0.81 CHRNB2 (0.74) CHRNB2CHRNA4MAPTGAAKMT2A
SCHEMBL5257852 0.81 CHRNB2 (0.58) CHRNB2CHRNA4MAPTGAAALDH1A1
SCHEMBL82236 0.79 MAPT (0.50) MAPTHTR3AGAAKMT2AMEN1
SCHEMBL6884588 0.79 CHRNB2 (0.61) CHRNB2CHRNA4MAPTHTR3AGAA
SCHEMBL16332226 0.79 CHRNB2 (0.60) CHRNB2CHRNA4MAPTKMT2AALDH1A1
SCHEMBL1433299 0.78 CHRNB2 (0.55) CHRNB2CHRNA4MAPTKMT2AMEN1
SCHEMBL594369 0.78 CHRNB2 (1.00) CHRNB2CHRNA4HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
WO-2025082316-A1 OPHTHALMIC FORMATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 苏州必扬医药科技有限公司 2025-04-24 WO disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
CN-119241532-A 1H-pyrazolo [4,3-c ] pyridine compound, composition and application thereof 深圳市塔吉瑞生物医药有限公司 2025-01-03 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 CHRNB2 3285/4885CHRNA4 4788/4885MAPT 4181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.